I believe 3 out of 5 patients showed at least a partial response so it appears that it does. One of those patients is still alive today with no evidence of disease after receiving a liver resection. For comparison, the two drugs we're trialing with, which is the SOC, only had an ORR of ~6% so if our mss CRC trial does 1/4th as good as it did in the basket trail, we will still more than double the ORR of the SOC. That should be good enough for BTD and then if we get good results on the PD-L1 like we expect, then in the Phase 3 we add an ICI and get approval pretty easily. They may even stop that trial and approve us if it's going well enough.